Multiple Sclerosis

Coffee may lower multiple sclerosis risk

Coffee may lower multiple sclerosis risk

Patients who regularly drank at least four cups of coffee a day were one-third less likely to have MS, compared with people who avoided coffee.

HPV vaccine not associated with increased multiple sclerosis risk

HPV vaccine not associated with increased multiple sclerosis risk

In primary and secondary analyses, vaccination was not associated with an increased risk of multiple sclerosis or other demyelinating diseases.

Dietary salt linked to an increase in multiple sclerosis activity

Dietary salt linked to an increase in multiple sclerosis activity

Patients with multiple sclerosis who had high levels of sodium intake were 3.4 times more likely to develop a new lesion.

AAN endorses cannabis for MS

AAN endorses cannabis for MS

The American Academy of Neurology has issued new evidence-based complementary and alternative medicine guidelines for multiple sclerosis.

FDA investigating PML in patient taking Gilenya

FDA investigating PML in patient taking Gilenya

A European patient with multiple sclerosis developed progressive multifocal leukoencephalopathy after taking the drug fingolimod.

FDA approves Tecfidera for MS

FDA approves Tecfidera for MS

By

Dimethyl fumarate is the third oral medication available to treat multiple sclerosis.

Combo MS therapy fails to cut relapse risk

Combo MS therapy fails to cut relapse risk

Combining interferon beta-1a and glatiramer acetate therapy does not provide added clinical benefit to patients with multiple sclerosis.

White matter integrity may indicate cognitive impairment in MS

White matter integrity may indicate cognitive impairment in MS

Diffusion tension imaging shows differences between cognitively preserved vs. impaired multiple sclerosis.

Retinal thinning may correspond with MS progression

Retinal thinning may correspond with MS progression

Thinning of the ganglion cell/inner plexiform of the retina may be a useful measure of the efficacy of novel MS therapies in future clinical trials.

Vitamin D may protect against MS

Vitamin D may protect against MS

Vitamin D may act as a protective factor for MS somewhere between late pregnancy and young adulthood, but no association for in utero exposure.

Alemtuzumab reduces MS relapses

Alemtuzumab reduces MS relapses

Two phase 3 studies show benefit with alemtuzumab as first-line therapy and for both nonrefractory and refractory MS.

Disease activity despite interferon predicts poor MS outcomes

Disease activity despite interferon predicts poor MS outcomes

In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes.

Sign Up for Free e-newsletters